Reproductive Health — MCQs
On this page
A 35-year-old woman with well-controlled type 1 diabetes requests contraception. She has no diabetic complications, her last HbA1c was 52 mmol/mol (6.9%), and her blood pressure is 124/78 mmHg. She has two children and has no plans for further pregnancies in the foreseeable future. She prefers not to take daily medication. Which contraceptive method is most appropriate?
A 50-year-old woman on sequential combined HRT for 18 months reports a 7-day episode of heavy vaginal bleeding occurring 10 days after her expected withdrawal bleed. She has no pain or other symptoms. Her last cervical screening 18 months ago was normal. Abdominal examination is unremarkable. What is the most appropriate initial investigation?
A 42-year-old woman using a copper IUD for contraception presents with increasingly heavy and painful periods over the past 6 months. Her periods now last 8 days with flooding and clots. She has mild dysmenorrhea. Examination reveals a bulky uterus and the IUD threads are visible. Pelvic ultrasound shows a uniformly enlarged uterus measuring 14 cm with multiple small intramural fibroids and the IUD is in normal position. Haemoglobin is 96 g/L. She has completed her family and wants effective contraception. What is the most appropriate management?
What is the mechanism of action of ulipristal acetate when used as emergency contraception?
A 58-year-old woman with premature ovarian insufficiency diagnosed at age 38 has been on HRT continuously since diagnosis. She is now concerned about continuing treatment and asks about stopping. She has no vasomotor symptoms currently and her last period was 20 years ago. She has no other medical history and no family history of breast cancer. What is the most appropriate advice?
A 26-year-old woman with epilepsy controlled on carbamazepine 400 mg twice daily requests contraception. She is in a stable relationship and prefers a highly effective long-acting method. Her BMI is 23 kg/m² and she has no other medical history. Which contraceptive method would provide the most reliable contraception for this patient?
A 48-year-old woman presents with a 6-month history of hot flushes and night sweats significantly affecting her quality of life. Her periods are irregular but ongoing. She has a BMI of 28 kg/m², blood pressure 132/84 mmHg, and no significant medical history. What initial investigations should be performed before considering HRT?
A 32-year-old woman attends for review of her levonorgestrel intrauterine system, which was fitted 18 months ago. She reports complete amenorrhea for the past 8 months and is concerned she might be pregnant. A urine pregnancy test is negative. She is otherwise well with no abdominal pain or abnormal discharge. On examination, the IUS threads are visible at the cervix. What is the most appropriate management?
A 55-year-old woman has been taking continuous combined HRT for 4 years for menopausal symptoms. She is concerned about breast cancer risk and asks about stopping treatment. Her vasomotor symptoms are now minimal. She had a total abdominal hysterectomy for fibroids at age 42. What is the most appropriate advice regarding her HRT?
A 45-year-old woman with irregular periods presents requesting contraception. She reports cycle lengths varying from 21 to 60 days over the past year. She has vasomotor symptoms occasionally. Her BMI is 24 kg/m², blood pressure 118/76 mmHg, and she is a non-smoker. She would like a method that might also help with her symptoms. What is the most appropriate contraceptive option?
Reproductive Health UK Medical PG Practice Questions and MCQs
Question 151: A 35-year-old woman with well-controlled type 1 diabetes requests contraception. She has no diabetic complications, her last HbA1c was 52 mmol/mol (6.9%), and her blood pressure is 124/78 mmHg. She has two children and has no plans for further pregnancies in the foreseeable future. She prefers not to take daily medication. Which contraceptive method is most appropriate?
- A. Combined oral contraceptive pill
- B. Etonogestrel subdermal implant (Correct Answer)
- C. Copper intrauterine device
- D. Depot medroxyprogesterone acetate injection
- E. Progesterone-only pill
Explanation: ***Etonogestrel subdermal implant*** - The **etonogestrel implant** is a **Long-Acting Reversible Contraceptive (LARC)**, which fits the patient's preference to avoid **daily medication** and offers high efficacy (>99%). - It is categorized as **UKMEC 1** for women with diabetes regardless of complications, as it has no significant impact on **carbohydrate metabolism** or **thrombotic risk**. *Combined oral contraceptive pill* - While it is **UKMEC 2** (benefits outweigh risks) for women with uncomplicated diabetes, it requires **daily administration**, which the patient specifically wants to avoid. - It carries a slightly higher **venous thromboembolism (VTE)** risk compared to progestogen-only or non-hormonal methods. *Copper intrauterine device* - The **copper IUD** is a highly effective **non-hormonal LARC** and is **UKMEC 1** for diabetic patients. - However, it may cause **heavier or more painful menstruation**, making the hormonal implant a more favourable option for cycle control in many women. *Depot medroxyprogesterone acetate injection* - This injection is **UKMEC 2** for diabetes but is associated with **weight gain**, which can complicate glycemic control in **Type 1 diabetes**. - There are also concerns regarding its impact on **lipid profiles** and a potential reduction in **bone mineral density** with long-term use. *Progesterone-only pill* - The **progesterone-only pill (POP)** is safe and **UKMEC 1** for this patient, but it does not meet her requirement for avoiding **daily medication**. - It is generally less effective than LARCs like the implant due to the risk of **user error** and missed doses.
Question 152: A 50-year-old woman on sequential combined HRT for 18 months reports a 7-day episode of heavy vaginal bleeding occurring 10 days after her expected withdrawal bleed. She has no pain or other symptoms. Her last cervical screening 18 months ago was normal. Abdominal examination is unremarkable. What is the most appropriate initial investigation?
- A. Transvaginal ultrasound to assess endometrial thickness (Correct Answer)
- B. Outpatient hysteroscopy and endometrial biopsy
- C. Repeat cervical cytology and HPV testing
- D. Serum CA-125 and pelvic ultrasound
- E. Switch to continuous combined HRT and review in 3 months
Explanation: ***Transvaginal ultrasound to assess endometrial thickness*** - In a woman on **sequential HRT** for more than 6 months, **unscheduled bleeding** (bleeding outside the expected withdrawal phase) requires investigation to rule out **endometrial hyperplasia** or **carcinoma**. - **Transvaginal ultrasound (TVUS)** is the gold-standard initial non-invasive tool; a thickness **>4 mm** or **>5 mm** (depending on local guidelines) necessitates further invasive testing. *Outpatient hysteroscopy and endometrial biopsy* - This is the definitive investigation for **histological diagnosis** but is considered the **second-line** step if the ultrasound shows an increased endometrial thickness or irregularity. - While accurate, it is more invasive and is typically reserved for cases where **TVUS** findings are abnormal or if symptoms persist despite a normal scan. *Repeat cervical cytology and HPV testing* - The patient’s symptoms are consistent with **uterine pathology** rather than cervical pathology, especially given the timing relative to her HRT cycle. - She had a **normal cervical screening** only 18 months ago, making a primary cervical cause less likely as the initial diagnostic focus. *Serum CA-125 and pelvic ultrasound* - **CA-125** is a biomarker used primarily for the evaluation of **ovarian cancer**, which typically presents with bloating, pelvic pain, or early satiety, rather than isolated heavy vaginal bleeding. - A standard **pelvic ultrasound** is less effective than a **transvaginal** approach for measuring the fine details of the **endometrial stripe**. *Switch to continuous combined HRT and review in 3 months* - **Unscheduled bleeding** in a patient who has been stable on HRT for 18 months must be investigated promptly and should not be managed by simply adjusting the medication. - Delaying investigation by 3 months to "review" risks missing a diagnosis of **endometrial malignancy** during a critical window.
Question 153: A 42-year-old woman using a copper IUD for contraception presents with increasingly heavy and painful periods over the past 6 months. Her periods now last 8 days with flooding and clots. She has mild dysmenorrhea. Examination reveals a bulky uterus and the IUD threads are visible. Pelvic ultrasound shows a uniformly enlarged uterus measuring 14 cm with multiple small intramural fibroids and the IUD is in normal position. Haemoglobin is 96 g/L. She has completed her family and wants effective contraception. What is the most appropriate management?
- A. Continue copper IUD with tranexamic acid and mefenamic acid for symptom control
- B. Remove copper IUD and fit levonorgestrel intrauterine system (Correct Answer)
- C. Remove copper IUD and commence combined oral contraceptive pill
- D. Remove copper IUD and arrange uterine artery embolization
- E. Remove copper IUD and refer for hysterectomy
Explanation: ***Remove copper IUD and fit levonorgestrel intrauterine system***- The **levonorgestrel intrauterine system (LNG-IUS)** is the first-line treatment for **heavy menstrual bleeding (HMB)** as it reduces blood loss by up to 95% and provides highly effective contraception.- It is appropriate for this patient as her **small intramural fibroids** do not distort the uterine cavity, and the uterus size (14 cm) is within the manageable range for insertion.*Continue copper IUD with tranexamic acid and mefenamic acid for symptom control*- The **copper IUD** is known to worsen **menorrhagia**, and continuing its use in an already **anemic (Hb 96 g/L)** patient is suboptimal.- Medical management with **tranexamic acid** is less effective than the LNG-IUS for long-term control of heavy bleeding associated with fibroids.*Remove copper IUD and commence combined oral contraceptive pill*- The **combined oral contraceptive (COCP)** is generally less effective than the **LNG-IUS** for reducing menstrual volume in cases of HMB.- Given the patient's age (42), there may be increased risks or **contraindications** compared to the localized hormonal effect of the IUS.*Remove copper IUD and arrange uterine artery embolization*- **Uterine artery embolization (UAE)** is a more invasive interventional radiology procedure typically reserved for larger, symptomatic fibroids.- It is not first-line when conservative, **medical-hormonal treatments** like the LNG-IUS have not yet been trialed.*Remove copper IUD and refer for hysterectomy*- **Hysterectomy** is a major surgical procedure and should only be considered when **conservative measures** have failed or are unsuitable.- Although the patient has completed her family, it is preferred to trial less invasive options for **symptom control** before proceeding to surgery.
Question 154: What is the mechanism of action of ulipristal acetate when used as emergency contraception?
- A. Inhibition of ovulation by delaying the LH surge through progesterone receptor modulation (Correct Answer)
- B. Direct toxic effect on the fertilized ovum
- C. Disruption of corpus luteum function leading to progesterone withdrawal
- D. Prevention of implantation by causing endometrial shedding
- E. Thickening of cervical mucus to prevent sperm penetration
Explanation: ***Inhibition of ovulation by delaying the LH surge through progesterone receptor modulation*** - **Ulipristal acetate** is a **selective progesterone receptor modulator (SPRM)** that inhibits or delays **follicular rupture** for at least 5 days, exceeding the lifespan of sperm. - Unlike levonorgestrel, it remains effective in delaying **ovulation** even when taken immediately before the **LH surge** begins, providing a wider window of efficacy. *Direct toxic effect on the fertilized ovum* - There is no medical evidence that ulipristal acetate acts as an **embryotoxic** agent or affects the viability of a **fertilized ovum**. - Its primary function occurs **pre-fertilization** by preventing the release of an egg from the ovary. *Disruption of corpus luteum function leading to progesterone withdrawal* - Ulipristal acetate does not primarily target the **corpus luteum**; its mechanism is focused on the **follicular phase** to prevent ovulation. - **Progesterone withdrawal** is typically a mechanism associated with medications used for medical termination of pregnancy, not the primary action of this emergency contraceptive. *Prevention of implantation by causing endometrial shedding* - Studies indicate that clinical doses used for emergency contraception do not significantly alter the **endometrium** enough to prevent **implantation**. - It is not an **abortifacient** and will not disrupt an existing pregnancy or cause the shedding of the uterine lining post-fertilization. *Thickening of cervical mucus to prevent sperm penetration* - While **progestin-only** daily contraceptives use **cervical mucus thickening** as a primary mechanism, this is not the mechanism for ulipristal acetate. - The drug is designed as a single-dose emergency intervention to counteract the high risk of pregnancy by specifically targeting the **ovulatory cycle**.
Question 155: A 58-year-old woman with premature ovarian insufficiency diagnosed at age 38 has been on HRT continuously since diagnosis. She is now concerned about continuing treatment and asks about stopping. She has no vasomotor symptoms currently and her last period was 20 years ago. She has no other medical history and no family history of breast cancer. What is the most appropriate advice?
- A. Stop HRT immediately as she has exceeded safe duration of use
- B. Continue HRT until at least age 51 (average age of natural menopause) then review (Correct Answer)
- C. Stop HRT but commence bisphosphonate therapy for bone protection
- D. Switch to lower-dose HRT preparation and continue for 2 more years
- E. Continue current HRT indefinitely as premature ovarian insufficiency requires lifelong treatment
Explanation: ***Continue HRT until at least age 51 (average age of natural menopause) then review***- In patients with **Premature Ovarian Insufficiency (POI)**, Hormone Replacement Therapy (HRT) acts as physiological replacement for endogenous estrogen, and the standard practice is to continue therapy until reaching the **average age of natural menopause** (approximately 51 years).- HRT is essential in these women to reduce the long-term risks of **osteoporosis**, **cardiovascular disease**, and cognitive decline associated with early estrogen deficiency; the risks (like breast cancer) are not significantly increased before age 51.*Stop HRT immediately as she has exceeded safe duration of use*- There is no specific "safe duration" limit for HRT in POI; stopping prematurely before the natural menopausal age increases the risk of **bone density loss** and **cardiovascular events**.- Decision-making at age 58 should be based on a **risk-benefit discussion** regarding current symptoms and long-term health, rather than an arbitrary immediate cessation.*Stop HRT but commence bisphosphonate therapy for bone protection*- **HRT** is considered the first-line treatment for bone protection in women with POI as it also addresses other metabolic and symptomatic needs that **bisphosphonates** do not.- Bisphosphonates are generally reserved for older, post-menopausal women or those with specific contraindications to hormonal therapy.*Switch to lower-dose HRT preparation and continue for 2 more years*- While tapering or switching to a **lower dose** can be done during a review, there is no clinical evidence supporting a mandatory "2-year" limit after reaching age 51.- Treatment should be **individualized** based on the patient's symptoms and health goals rather than following a rigid two-year extension period.*Continue current HRT indefinitely as premature ovarian insufficiency requires lifelong treatment*- While some women may choose to continue HRT longer for symptom control, it is not strictly required **indefinitely**; treatment should be reviewed periodically after the age of natural menopause.- Lifelong treatment carries different risk profiles (such as **breast cancer risk**) as the patient ages, shifting the balance from physiological replacement to pharmacological supplementation.
Question 156: A 26-year-old woman with epilepsy controlled on carbamazepine 400 mg twice daily requests contraception. She is in a stable relationship and prefers a highly effective long-acting method. Her BMI is 23 kg/m² and she has no other medical history. Which contraceptive method would provide the most reliable contraception for this patient?
- A. Levonorgestrel intrauterine system 52 mg
- B. Etonogestrel subdermal implant 68 mg
- C. Depot medroxyprogesterone acetate injection
- D. Combined oral contraceptive pill with 30 mcg ethinylestradiol
- E. Copper intrauterine device (Correct Answer)
Explanation: ***Copper intrauterine device***- **Carbamazepine** is a potent **liver enzyme inducer** that speeds up the metabolism of hormonal contraceptives, but it has no effect on the **copper intrauterine device (Cu-IUD)** because it is **non-hormonal**.- The **Cu-IUD** provides the most reliable contraception in this scenario, as it is a **Long-Acting Reversible Contraceptive (LARC)** with a failure rate of less than 1% regardless of medication interactions.*Levonorgestrel intrauterine system 52 mg*- While the **LNG-IUS** acts primarily locally, there is a theoretical risk that **enzyme-inducing drugs** could reduce its efficacy through systemic absorption, making it less ideal than the **Cu-IUD**.- Although it is often classified as **UKMEC 2** (benefits outweigh risks), the **Cu-IUD** remains the **gold standard** for reliability when drug interactions are a concern.*Etonogestrel subdermal implant 68 mg*- The **etonogestrel implant** is highly sensitive to **enzyme induction**, which significantly lowers progestogen levels and increases the risk of **contraceptive failure**.- It is classified as **UKMEC 3** (risks usually outweigh benefits) for women taking **carbamazepine**, making it an unsuitable choice for this patient.*Depot medroxyprogesterone acetate injection*- **DMPA** is less affected by **enzyme inducers** than oral methods, but some guidelines suggest the **dosing interval** might need to be shortened to maintain efficacy.- While it can be used (**UKMEC 2**), it is not as reliable as the **Cu-IUD** which removes the risk of metabolic interaction entirely.*Combined oral contraceptive pill with 30 mcg ethinylestradiol*- **Carbamazepine** induces the **CYP3A4 enzyme system**, leading to rapid breakdown of **ethinylestradiol** and increasing the risk of breakthrough ovulation.- Even higher doses of estrogen (at least **50 mcg**) are often insufficient to overcome this interaction, making **COCPs** a poor choice for those taking **enzyme-inducing antiepileptics**.
Question 157: A 48-year-old woman presents with a 6-month history of hot flushes and night sweats significantly affecting her quality of life. Her periods are irregular but ongoing. She has a BMI of 28 kg/m², blood pressure 132/84 mmHg, and no significant medical history. What initial investigations should be performed before considering HRT?
- A. Follicle-stimulating hormone, luteinizing hormone, and estradiol levels
- B. Full blood count, thyroid function tests, and lipid profile
- C. Transvaginal ultrasound and endometrial biopsy
- D. Mammography and bone density scan
- E. Blood pressure measurement and assessment of cardiovascular risk only (Correct Answer)
Explanation: ***Blood pressure measurement and assessment of cardiovascular risk only*** - In women over **45 years** with typical symptoms like hot flushes and irregular periods, the diagnosis of perimenopause is primarily **clinical** and does not require routine hormonal blood tests. - Essential pre-HRT screening focuses on identifying **contraindications** such as uncontrolled **hypertension** or high **cardiovascular risk** to ensure the safest HRT regimen and delivery method. *Follicle-stimulating hormone, luteinizing hormone, and estradiol levels* - **FSH** and **estradiol** levels fluctuate significantly during the **perimenopause**, making them unreliable and unnecessary for diagnosis in women over age 45. - NICE guidelines specifically advise against using these tests to diagnose menopause in this age group as they do not change clinical management. *Full blood count, thyroid function tests, and lipid profile* - These tests are not routinely required unless the patient presents with specific symptoms suggestive of **anemia**, **thyroid dysfunction**, or metabolic disorders. - While **thyroid disease** can mimic menopausal symptoms, it is not a standard initial investigation for a classic clinical presentation of perimenopause. *Transvaginal ultrasound and endometrial biopsy* - These are invasive investigations reserved for **abnormal uterine bleeding** or a thickened **endometrial stripe**, rather than routine menopause screening. - Perimenopausal irregular periods are expected, and these tests are only indicated if there is **intermenstrual bleeding** or postmenopausal bleeding. *Mammography and bone density scan* - Routine **mammography** is not required before HRT unless the patient is due for her standard national breast screening program or has a suspicious breast lump. - **DEXA scans** are not routine pre-HRT investigations unless the patient has specific risk factors for **osteoporosis** or high fracture risk scores.
Question 158: A 32-year-old woman attends for review of her levonorgestrel intrauterine system, which was fitted 18 months ago. She reports complete amenorrhea for the past 8 months and is concerned she might be pregnant. A urine pregnancy test is negative. She is otherwise well with no abdominal pain or abnormal discharge. On examination, the IUS threads are visible at the cervix. What is the most appropriate management?
- A. Arrange pelvic ultrasound to confirm IUS position and exclude pregnancy
- B. Perform serum beta-hCG to definitively exclude pregnancy
- C. Remove and replace the IUS as amenorrhea suggests device failure
- D. Reassure that amenorrhea is a common and expected side effect of the levonorgestrel IUS (Correct Answer)
- E. Arrange hysteroscopy to assess endometrial changes
Explanation: ***Reassure that amenorrhea is a common and expected side effect of the levonorgestrel IUS*** - **Amenorrhea** is a common and expected side effect of the **levonorgestrel intrauterine system (LNG-IUS)**, occurring in approximately 20% of users by one year due to **endometrial suppression**. - Since the **urine pregnancy test is negative** and the **IUS threads are visible**, no further investigations are required for a patient who is otherwise asymptomatic. *Arrange pelvic ultrasound to confirm IUS position and exclude pregnancy* - **Pelvic ultrasound** is not indicated because the **IUS threads are visible** during examination, confirming the device is in the correct position. - Ultrasound to exclude pregnancy is unnecessary as the **urine pregnancy test** is already negative and the patient is asymptomatic. *Perform serum beta-hCG to definitively exclude pregnancy* - Modern **urine pregnancy tests** are highly sensitive; a negative result 8 months into amenorrhea is sufficient to exclude pregnancy. - **Serum beta-hCG** is typically reserved for cases where an **ectopic pregnancy** is suspected or when urine tests are inconclusive. *Remove and replace the IUS as amenorrhea suggests device failure* - **Amenorrhea** is a sign of effective **local progestogen action** on the endometrium, not a sign of device failure or loss of contraceptive efficacy. - Routine removal is inappropriate unless the device is **expired**, **displaced**, or the patient requests removal due to side effects. *Arrange hysteroscopy to assess endometrial changes* - **Hysteroscopy** is an invasive procedure not indicated for managing **expected side effects** of hormonal contraception like amenorrhea. - It is generally reserved for investigating **abnormal uterine bleeding**, postmenopausal bleeding, or when an IUS is "lost" and cannot be found via ultrasound.
Question 159: A 55-year-old woman has been taking continuous combined HRT for 4 years for menopausal symptoms. She is concerned about breast cancer risk and asks about stopping treatment. Her vasomotor symptoms are now minimal. She had a total abdominal hysterectomy for fibroids at age 42. What is the most appropriate advice regarding her HRT?
- A. Stop HRT immediately as the recommended maximum duration of 5 years is approaching
- B. Switch from combined HRT to estrogen-only HRT and continue (Correct Answer)
- C. Continue current combined HRT as benefits outweigh risks given minimal symptoms
- D. Gradually taper the HRT dose over 3-6 months before stopping
- E. Stop combined HRT and commence progesterone-only pill for symptom control
Explanation: ***Switch from combined HRT to estrogen-only HRT and continue*** - The patient has undergone a **total abdominal hysterectomy**, meaning she no longer has a uterus and therefore does not require **progestogen** for endometrial protection; switching to **estrogen-only HRT** is the appropriate clinical step. - **Estrogen-only HRT** is associated with a **lower risk of breast cancer** compared to combined HRT, which directly addresses the patient's primary concern while effectively managing her minimal menopausal symptoms. *Stop HRT immediately as the recommended maximum duration of 5 years is approaching* - There is no fixed **maximum duration** for HRT; treatment duration should be individualized based on the balance of ongoing **menopausal symptoms**, risks, and benefits, with regular review. - Abrupt cessation of HRT can lead to a **recurrence of vasomotor symptoms**, and decisions to stop should be a shared discussion rather than based on an arbitrary time limit. *Continue current combined HRT as benefits outweigh risks given minimal symptoms* - Continuing **progestogen** in a woman who has had a hysterectomy provides no clinical benefit as there is no endometrium to protect, and it unnecessarily increases the risk of **breast cancer** and venous thromboembolism. - Given the patient's specific concern about **breast cancer risk**, maintaining an unnecessary combined formulation is not appropriate and could exacerbate her anxiety. *Gradually taper the HRT dose over 3-6 months before stopping* - While **gradual tapering** can be considered to reduce the likelihood of symptom recurrence, it is not a mandatory safety measure, and clinical evidence does not consistently demonstrate its superiority over abrupt cessation for preventing relapse. - This option still fails to address the fundamental issue of continuing **progestogen** in a patient without a uterus, which is the primary inappropriate aspect of her current regimen. *Stop combined HRT and commence progesterone-only pill for symptom control* - The **progesterone-only pill (POP)** is primarily a contraceptive method and is not an effective treatment for **menopausal vasomotor symptoms** as it does not address **estrogen deficiency**. - Commencing a **progestogen-only** preparation without estrogen would be inappropriate for managing menopausal symptoms and would not mitigate the risks associated with the previous combined HRT effectively.
Question 160: A 45-year-old woman with irregular periods presents requesting contraception. She reports cycle lengths varying from 21 to 60 days over the past year. She has vasomotor symptoms occasionally. Her BMI is 24 kg/m², blood pressure 118/76 mmHg, and she is a non-smoker. She would like a method that might also help with her symptoms. What is the most appropriate contraceptive option?
- A. Progesterone-only pill
- B. Combined oral contraceptive pill (Correct Answer)
- C. Levonorgestrel intrauterine system
- D. Copper intrauterine device
- E. Progesterone-only implant
Explanation: ***Combined oral contraceptive pill*** - For women under **age 50** who are non-smokers and have no contraindications, the **Combined oral contraceptive pill (COCP)** is ideal for providing contraception and regulating **irregular menstrual cycles**.- The **estrogen component** also effectively alleviates **vasomotor symptoms** and helps maintain **bone mineral density**, addressing the patient's desire for symptom management. *Progesterone-only pill* - While a safe contraceptive option for women over 40, the **progesterone-only pill (POP)** does not contain estrogen, therefore it cannot relieve **vasomotor symptoms**.- It may also lead to **irregular bleeding** or unscheduled spotting, which would not improve the patient's existing cycle irregularities. *Levonorgestrel intrauterine system* - The **LNG-IUS** is highly effective for contraception and managing **heavy menstrual bleeding**, but it does not contain estrogen and therefore cannot alleviate **vasomotor symptoms**.- Although it can be used as the progestogen component of **HRT**, the patient would still require separate estrogen therapy to treat her hot flushes. *Copper intrauterine device* - The **copper IUD** provides highly effective non-hormonal contraception but offers **no relief** for **perimenopausal symptoms** such as irregular periods or vasomotor symptoms.- It is known to potentially cause **heavier or more painful periods**, which could exacerbate the patient's existing menstrual irregularities. *Progesterone-only implant* - The **etonogestrel implant** provides long-acting reversible contraception but, as a progesterone-only method, it does not contain estrogen to suppress **vasomotor symptoms**.- It frequently causes **unpredictable bleeding patterns**, which would not provide the cycle regularity and symptom relief that this patient desires.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free